Watch ELVN. Know when insiders buy.
One email the day a filing lands. Free.
ELVN
Enliven Therapeutics, Inc.
54.32
−1.91 −3.40%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
47
WATCH · shorts 47
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4BP/E —DIV YIELD —FCF YIELD -1.68%REV TTM —NET INCOME −$105.9MNET CASH —52W 15.14 – 61.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$37.2M | −$32.5M | — | -0.49 | −$18.5M | $99K | −$18.6M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$27.8M | −$23.6M | — | -0.38 | −$19.3M | $0 | −$19.3M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$34.3M | −$29.7M | — | -0.48 | −$15.8M | $0 | −$15.8M | Mar 3 |
| Q3 2025 · Sep 30 | — | — | — | −$25.1M | −$20.1M | — | -0.32 | −$13.3M | −$1K | −$13.3M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$28.6M | −$25.3M | — | -0.49 | −$17.1M | $139K | −$17.2M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$31.7M | −$28.5M | — | -0.57 | −$24.1M | $20K | −$24.1M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$26.9M | −$23.2M | — | -0.46 | −$17.2M | $0 | −$17.2M | Mar 3 |
| Q3 2024 · Sep 30 | — | — | — | −$27.1M | −$23.2M | — | -0.48 | −$12.2M | $22K | −$12.2M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$24.6M | −$19.9M | — | -0.41 | −$20.4M | $2K | −$20.4M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$26M | −$22.7M | — | -0.54 | −$23.4M | $20K | −$23.4M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$22.7M | −$19.4M | — | -0.46 | −$12.5M | $14K | −$12.5M | Mar 13 |
| Q3 2023 · Sep 30 | — | — | — | −$24.2M | −$20.8M | — | -0.51 | −$15.9M | $16K | −$15.9M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$119.7M | −$103.7M | — | -1.83 | −$70.3M | $158K | −$70.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$104.6M | −$89M | — | -1.89 | −$73.2M | $44K | −$73.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$83.5M | −$71.6M | — | -2.01 | −$61.3M | $149K | −$61.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$38.8M | −$37.7M | — | -12.05 | −$32.1M | $612K | −$32.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$51.4M | −$51.4M | — | -2.37 | −$46.8M | $12K | −$46.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$41.7M | −$41.4M | — | -3.53 | −$37.4M | $18K | −$37.4M | — | — |
Every number comes from Enliven Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.